Market Overview
The Global Mammalian Cell Fermentation Technology Market is expected to reach a value of
USD 45.5 billion in 2023, and it is further anticipated to reach a market value of
USD 102.6 billion by 2032 at a
CAGR of 9.4%.
The Global Mammalian Cell Fermentation Technology Market is the entire economic environment related to producing biopharmaceuticals using mammalian cell fermentation technology. This critical process involves using mammalian cells, in particular, cellular lines like Chinese Hamster Ovary (CHO) cells to provide a set of biologics such as therapeutic proteins monoclonal antibodies vaccines hormones enzymes, and the rest. Significant ingredients of this market include many bioprocessing technologies, detailed cell lines, and cultures of diverse types along with end users like biopharmaceutical firms, Contract Manufacturing Organizations (CMOs), and academic institutions.
Key Takeaways
- Chinese Hamster Ovary (CHO) cell fermentation stands out as the dominant and preferred choice based on type in the global mammalian cell fermentation technology market as it holds 67.5% of the market share in 2023.
- Monoclonal antibodies exert their dominance in the context of application with 44.3% of the market share in 2023.
- Biopharmaceutical companies dominate the global mammalian cell fermentation technology market based on end-user segment as it holds 54.9% of the market share in 2023.
- North America has emerged as a dominant force in the global mammalian cell fermentation technology market as it holds 39.0% of the market share in 2023.
- Following North America Asia Pacific shows the highest growth potential with the highest CAGR in 2023.
Market Dynamic
Noteworthy trends consist of the adoption of single-use technologies, a focus on sustainability, and advancements in personalized treatment, all contributing to the market's growth and providing opportunities for innovation and development inside the field of mammalian cellular fermentation technology. Continuous technological improvements, specifically in bioreactor layout and method optimization, enhance performance and scalability. The growing global need for biopharmaceuticals pushed through elements consisting of a growing old population and advancements in biologics improvement, serves as a pivotal growth motive force.
The enterprise is adapting to the trend of personalized medication, incorporating mammalian mobile fermentation for cures inclusive of cell and gene remedies. Global health emergencies, just like the COVID-19 pandemic, underscore the critical role of rapid and scalable biopharmaceutical manufacturing, with mammalian mobile fermentation technology playing an imperative role. Regulatory modifications, ongoing studies and development, market consolidation through mergers and partnerships, sustainability efforts, the adoption of unmarried-use technology, and the access of rising economies into the biopharmaceutical industry collectively shape the market's panorama.
Research Scope and Analysis
By Type
Chinese Hamster Ovary (CHO) cell fermentation stands out as the dominant and preferred choice based on type in the global mammalian cell fermentation technology market as it holds 67.5% of the market share in 2023 and is projected to show subsequent growth in the upcoming year as well. Notably, CHO cells exhibit human-like protein production capabilities, crucial for biopharmaceuticals' correct folding and modifications. With a proven track record seen in the successful production of numerous commercially available biologics and monoclonal antibodies, CHO cells benefit from extensive industry experience.
Their scalability, adaptability to serum-free conditions, well-established protocols, regulatory acceptance, and availability of advanced genetic tools contribute to their market dominance. Furthermore, CHO cells offer flexibility in glycosylation patterns and have become an industry standard for biopharmaceutical production, contributing to a level of standardization in the manufacturing process. While CHO cells are predominant, the diversity of cell lines used, such as Human Embryonic Kidney (HEK) cells and Baby Hamster Kidney (BHK) cells, reflects specific applications in mammalian cell fermentation technology. The choice of cell line depends on the specific requirements of the biopharmaceutical product and production process goals.
By Application
Monoclonal antibodies exert their dominance in the context of software with 44.3% of market share in 2023 and are expected to show growth in the approaching duration of 2023 to 2032. Monoclonal antibodies (mAbs) occupy a central role inside the mammalian cellular fermentation technology marketplace due to their enormous healing programs, mainly in cancer, autoimmune disorders, and infectious sicknesses.
As important components of the biologics market, monoclonal antibodies' complex manufacturing techniques necessitate precise manipulation, a need met correctly using the mammalian mobile fermentation tech. The excessive market requirement for an enormous cost of monoclonal antibodies, coupled with their various healing makes use of, pressure a focus on scalable and green manufacturing techniques.
Mammalian mobile systems provide advantages in humanization, specificity, and vital publish-translational modifications, making sure safety and efficacy in therapeutic programs. The scientific fulfillment and regulatory approval of many monoclonal antibodies contribute to sustained funding and research, similarly solidifying mammalian cellular fermentation's dominance in meeting the evolving production wishes of this important therapeutic category.
By End User
Biopharmaceutical companies dominate the global mammalian cell fermentation technology market based on end-user segment as it holds 54.9% of the market share in 2023. Biopharmaceutical companies exert significant influence in the mammalian cell fermentation technology market due to their in-house production of biologics, reliance on scalable processes to meet global demand, and the need for customization and flexibility in their manufacturing processes.
Maintaining control over intellectual property, ensuring regulatory compliance, and strategically managing the supply chain are key factors driving their preference for in-house production. This approach enables biopharmaceutical companies to accelerate time-to-market, integrate new technologies from extensive research and development investments, and maintain a global market presence. Despite their dominance, Contract Manufacturing Organizations (CMOs) and Contract Development and Manufacturing Organizations (CDMOs) also play a noteworthy role, offering flexibility and specialized expertise, often leading to collaborative arrangements for specific projects or addressing capacity constraints.
The Mammalian Cell Fermentation Technology Market Report is segmented on the basis of the following:
By Type
- Chinese Hamster Ovary (CHO) Cell Fermentation
- Human Embryonic Kidney (HEK) Cell Fermentation
- Baby Hamster Kidney (BHK) Cell Fermentation
- Murine Myeloma Cell Fermentation
- Others
By Application
- Monoclonal Antibodies
- Recombinant Proteins
- Vaccines
- Hormones
- Enzymes
- Others
By End User
- Biopharmaceutical Companies
- CMOs & CDMOs
- Academic & Research Institutes
Regional Analysis
The global mammalian cell fermentation technology market is led by North America, which has 39.0% of the market share as of 2023 and it is estimated to show growth during the forecast period from 2023 to 2032. The dominance of North America in this market can be attributed to several factors. Traditionally, North America especially the US has been in a key position in this market as it is home to many remarkable research establishments and biotechnology centers which nurture innovations concerning mammalian cell fermentation technology.
These technologies are heavily used by an established biopharmaceutical industry that is dominated by global leaders. The leadership of North America in the industry is attributed to strengthened healthcare infrastructure, a substantial amount spent on research and development, favorable regulatory landscape that allows easy accessibility of ample capital for investment coupled with strategic collaborations. Responsiveness of the region to market signals regarding biologics adds weight, which is an additional factor that reinforces its dominant position due to global leadership demonstrated by key companies headquartered in North America.
By Region
North America
Europe
- Germany
- The U.K.
- France
- Italy
- Russia
- Spain
- Benelux
- Nordic
- Rest of Europe
Asia-Pacific
- China
- Japan
- South Korea
- India
- ANZ
- ASEAN
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of Latin America
Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Israel
- Egypt
- Rest of MEA
Competitive Landscape
North America has emerged as a dominant pressure inside the international mammalian cellular fermentation technology market as it holds 39.0% of the market percentage in 2023 and is expected to show a subsequent increase in the imminent period of 2023 to 2032. North America, especially America, has historically played a pivotal function in this marketplace as it houses numerous prestigious research establishments and biotechnology hubs that foster innovation in the mammalian cell fermentation tech. A well-installed biopharmaceutical agency, with principal international game enthusiasts’ gift, is based heavily on the one’s technology.
North America's sturdy healthcare infrastructure, huge investments in research and improvement, supportive regulatory environment, right of entry to sufficient capital, and strategic collaborations make contributions to its management. The area's responsiveness to market needs for biologics, coupled with the worldwide leadership of key groups centered in North America, reinforces its dominant role. While acknowledging North America's historic significance, it's miles critical to apprehend that different regions, along with Europe and Asia-Pacific, additionally play significant roles within the evolving dynamics of the global mammalian cell fermentation technology market.
Some of the prominent players in the Global Mammalian Cell Fermentation Technology Market are:
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher
- Lonza
- F. Hoffmann-La Roche Ltd
- Sartorius AG
- AstraZeneca
- Bristol-Myers Squibb
- Amgen
- Gilead Sciences
- Moderna Inc.
- Regeneron Pharmaceuticals
- Other Key Players
COVID-19 Pandemic & Recession: Impact on the Global Mammalian Cell Fermentation Technology Market:
The COVID-19 pandemic and monetary recessions have potential implications for the worldwide mammalian cellular fermentation era marketplace. Supply chain disruptions because of the pandemic have brought about delays and accelerated expenses in manufacturing, impacting the availability of uncooked materials. Research and development priorities also confronted a shift closer to technology related to vaccine production and infectious disorder remedies.
Moreover, monetary recessions additionally cause price range constraints, affecting investments in new technologies, including mammalian mobile fermentation. Fluctuations in demand for biopharmaceuticals can also arise, pushed by changes in clinical remedy needs. Government intervention and funding, inclusive of stimulus programs, undoubtedly influenced the increase of the marketplace. Companies may additionally undertake automation and performance measures to cut prices during financially demanding situations. The precise effect will depend on the pandemic's nature, duration, common monetary conditions, and regulatory environment.
Recent Developments
- In September 2023, 908 Devices launched MAVERICK, a turn-key device using Raman spectroscopy for real-time monitoring of glucose, lactate, and biomass in mammalian cell cultures, overcoming traditional analyzer complexities, enhancing process development in biopharmaceuticals.
- In July 2023, Lonza launched the TheraPRO CHO media system, a new cell culture platform that simplifies processes and optimizes their productivity & protein quality by using GS-CHO cell lines which will help the company expand its product portfolio.
- In June 2023, Culture Biosciences and Cytiva collaborate to advance upstream bioprocessing, offering customers enhanced digital technologies for efficient scaling. Cytiva's Bioreactor Scaler tool integrates Culture's 250 mL bioreactor, facilitating seamless scaling and de-risking activities, aiming to bring innovation and predictability to therapeutic manufacturing.
- In March 2023, KBI Biopharma's Geneva facility releases its inaugural FIH manufacturing batch in compliance with cGMP standards, showcasing capabilities in cell line development and biologics manufacturing just five months after opening.
- In January 2023, Ginkgo Bioworks opened Bioworks7, a state-of-the-art biological engineering foundry, expanding its research and development capabilities in mammalian programming, cell and gene therapy, and biomanufacturing. Equipped with advanced robotics and dedicated iPSC workspaces, the 6,600-square-foot facility at the Boston headquarters enhances Ginkgo's capacity to collaborate with partners, advancing innovations in the biopharmaceutical space.
Report Details
| Report Characteristics |
| Market Size (2023) |
USD 45.5 Bn |
| Forecast Value (2032) |
USD 102.6 Bn |
| CAGR (2023-2032) |
9.4% |
| Historical Data |
2018 – 2023 |
| Forecast Data |
2024 – 2033 |
| Base Year |
2023 |
| Estimate Year |
2024 |
| Report Coverage |
Market Revenue Estimation, Market Dynamics, Competitive Landscape, Growth Factors and etc. |
| Segments Covered |
By Type (Chinese Hamster Ovary (CHO) Cell
Fermentation, Human Embryonic Kidney (HEK) Cell
Fermentation, Baby Hamster Kidney (BHK) Cell
Fermentation, Murine Myeloma Cell Fermentation,
and Others), By Application (Monoclonal Antibodies,
Recombinant Proteins, Vaccines, Hormones,
Enzymes, and Others), By End User
(Biopharmaceutical Companies, CMOs & CDMOs, and
Academic & Research Institutes) |
| Regional Coverage |
North America – The US and Canada; Europe – Germany, The UK, France, Russia, Spain, Italy, Benelux, Nordic, & Rest of Europe; Asia- Pacific– China, Japan, South Korea, India, ANZ, ASEAN, Rest of APAC; Latin America – Brazil, Mexico, Argentina, Colombia, Rest of Latin America; Middle East & Africa – Saudi Arabia, UAE, South Africa, Turkey, Egypt, Israel, & Rest of MEA
|
| Prominent Players |
Thermo Fisher Scientific Inc., Merck KGaA, Danaher,
Lonza, F. Hoffmann-La Roche Ltd, Sartorius AG,
AstraZeneca, Bristol-Myers Squibb, Amgen, Gilead
Sciences, Moderna Inc., Regeneron Pharmaceuticals,
and Other Key Players |
| Purchase Options |
We have three licenses to opt for: Single User License (Limited to 1 user), Multi-User License (Up to 5 Users), and Corporate Use License (Unlimited User) along with free report customization equivalent to 0 analyst working days, 3 analysts working days and 5 analysts working days respectively. |